Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific Cytotoxic T cells in vitro

International Journal of Cancer

Volumn 104, Issue 4, 2003, Pages 437-445

  Correale, Pierpaolo ^a   Aquino, Angelo ^b   Giuliani, Antonio ^b   Pellegrini, Monia ^a   Micheli, Lucia ^a   Cusi, Maria Grazia ^a   Nencini, Cristina ^a   Petrioli, Roberto ^a   Prete, Salvatore ^b   De Vecchis, Liana ^b   Turriziani, Mario ^b   Giorgi, Giorgio ^a   Bonmassar, Enzo ^b   Francini, Guido ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

5 fluorouracil; CEA; Cytotoxic T lymphocytes; Immune sensitization

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; HLA A ANTIGEN; IMMUNOMODULATING AGENT; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; COLON CANCER; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG MECHANISM; DRUG SENSITIVITY; HLA TYPING; HUMAN; HUMAN CELL; IMMUNIZATION; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; TARGET CELL DESTRUCTION;

ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; COLONIC NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; FLUOROURACIL; HLA-A ANTIGENS; HUMANS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0037457485     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10969     Document Type: Article

References (45)

1. Thompson JA, Grunert F, Zimmermann W. Carcino embryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 1991:5:344-66.
2. Kantor J, Irvine K, Abrams S, Kaufman H, DiPietro J, Schlom J. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst 1992;84:1059-61.
3. Kantor J, Irvine K, Abrams S, Snoy P, Olsen R, Greiner J, Kaufman H, Eggensperger D, Schlom J. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. Cancer Res 1992;52:6917-25.
4. Foon KA, John WJ, Chakraborty M, Sherratt A, Garrison J, Flett M, Bhattacharya-Chatterjee M. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. Clin Cancer Res 1997;3:1267-76.
5. Kass E, Schlom J, Thompson J, Guadagni F, Graziano P, Greiner JW. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res 1999;59:676-83.
6. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcino-embryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995;87:982-90.
7. Evans TR, Kaye SB. Vaccine therapy for cancer-Fact or fiction? Q J Med 1999;92:299-307.
8. Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, Schlom J, Ryback ME, Lyerly HK. A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 1999;5:1331-8.
9. von Mehren M, Arlen P, Tsang KY, Rogatko A, Meropol N, Cooper HS, Davey M, McLaughlin S, Schlom J, Weiner LM. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin Cancer Res 2000:6:2219-28.
10. von Mehren M, Arlen P, Gulley J, Rogatko A, Cooper HS, Meropol NJ, Atpaugh RK, Davey M, McLaughlin S, Beard MT, Tsang KY, Schlom J, Weiner LM. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 2001;7:1181-91.
11. Maas IW, Boven E, Pinedo HM, Schluper HM, Haisma HJ. The effects of gamma-interferon combined with 5-fluorouracil or 5-fluoro-2′-deoxyuridine on proliferation and antigen expression in a panel of human colorectal cancer cell lines. Int J Cancer 1991;48:749-56.
12. Prete SP, Aquino A, Masci G, Orlando L, Giuliani A, De Sanctis S, De Vecchis L, De Filippi R, Greiner JW, Bonmassar E, Graziani G. Drug-induced changes of carcinoembryonic antigen expression in human cancer cells: effects of 5-fluorouracil. J Pharmacol Exp Ther 1996;279:1574-81.
13. Aquino A, Prete S, Greiner JW, Giuliani A, Graziani G, Turriziani M, De Filippi R, Masci G, Bonmassar E, De Vecchis L. Effects of the combined treatment with 5-fluorouracil, gamma-interferon or folinic acid on carcinoembryonic antigen expression in colon cancer cells. Clin Cancer Res 1998;4:2473-81.
14. Storkus WJ, Howell DN, Salter RD, Dawson JR, Creswell P. NK susceptibility varies inversely with target cell Class I HLA antigen expression. J Immunol 1987;138:1657-9.
15. Miyoshi I, Kubonishi J, Yoshimoto S. Type-C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukemic T-cells. Nature 1981;294:770-1.
16. Parker KC, Bednarek MA, Coligan J E. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994;152:163-75.
17. Boyum A. A one-stage procedure for isolation of granulocytes and lymphocytes from human blood. General sedimentation properties of white blood cells in a lg gravity field. Scand J Clin Lab Invest 1968;97(Suppl):51-76.
18. Guadagni F, Witt PL, Robbins PF, Schlom J, Greiner WJ. Regulation of carcinoembryonic antigen expression in different human colorectal tumor cells by interferon-α. Cancer Res 1990;50:6248-55.
19. Grem JL. 5-Fluoropyrimidines. In: Chabner BA, Longo DL, eds. Cancer chemotherapy and biotherapy: principles and practice. 2nd ed. Philadelphia: Lippincott-Raven, 1996. 149-63.
20. Wang RF, Rosenberg SA. Human tumor antigens for cancer vaccine development. Immunol Rev 1999;170:85-100.
21. Zinkernagel RM. Immunity against solid tumors? Int J Cancer 2001;93:1-5.
22. Carrabba M, Parmiani G, Rivoltini L. Cancer vaccines. Tumori 2000; (Suppl)86:S33-7.
23. Van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 1997;9:684-93.
24. Dorothee G, Ameyar M, Bettaieb A, Vergnon I, Echchakir H, Bouziane M, Chouaib S, Mami-Chouaib F. Role of Fas and granule exocytosis pathways in tumor-infiltrating T lymphocyte-induced apoptosis of autologous human lung-carcinoma cells. Int J Cancer 2001;91:772-7.
25. Mavligit G, Gutterman JU, Burgess MA, Khankhanian N, Sibert GB, Speer JF, Reed RC, Jubert AV, Martin RC, MacBridge CM, Copeland EM, Gehan EA, Hersh EM. Adjuvant immunotherapy and chemoimmunotherapy in colorectal cancer of the Dukes' C classification. Preliminary clinical results. Cancer 1975;36:2421-7.
26. Bedikian AY, Valdivieso M, Mavligit G, Burgess MA, Rodriguez V, Bodey GP. Sequential chemoimmunotherapy of colorectal cancer. evaluation of methotrexate, Baker's Antifol and levamisole. Cancer 1978;42:2169-76.
27. Richards F. 2nd, Muss HB, Cooper RM, White DR, Stuart JJ, Howard V, Barnes P, Rhyne L, Spurr CL. Chemotherapy versus chemoimmunotherapy in advanced adenocarcinoma of the colon and rectum: a prospective randomized study. Cancer 1979;43:91-6.
28. Heinzer H, Huland E, Huland H. Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer. World J Urol 2001;19:111-9.
29. Elias L, Binder M, Mangalik A, Clark D, Morrinson B, Altobelli KK, Smith A. Pilot trial of infusional 5-fluorouracil, interleukin-2, and subcutaneous interferon-alpha for advanced renal cell carcinoma. Am J Clin Oncol 1999:22:156-61.
30. Lauro S, Bordin F, Trasatti L, Lanzetta G, Della Rocca C, Frati L. Concurrent chemoimmunotherapy in metastatic clear cell sarcoma: a case report. Tumori 1999;85:512-4.
31. Lau WY, Leung TW, Lai BS, Liew CT, Ho SK, Yu SC, Tang AM. Preoperative systemic chemoimmunotherapy and sequential resection of unresectable hepatocellular carcinoma. Ann Surg 2001;233:236-41.
32. Correale P, Caraglia M, Fabrocini A, Guarrasi R, Pepe S, Patella V, Marone G, Pinto A, Bianco AR, Tagliaferri P. Bryostatin 1 enhances lymphokine activated killer sensitivity and modulates the beta 1 integrin profile of cultured human tumor cells. Anticancer Drugs 1995;6:285-90.
33. Correale P, Tagliaferri P, Celio L, Genua G, Montagnani S, Bianco AR. Verapamil upregulates sensitivity of human colon and breast cancer cells to LAK-cytotoxicity in vitro. Eur J Cancer 1991;27:1393-5.
34. Tagliaferri P, Correale P, Mottola M, de Simone G, Montesarchio V, Matano E, Rea A, Morabito A, Famiani M, Ciardiello F, Tortora G, Caraglia M, Barile C, Palmieri G, Bianco AR. High-dose recombinant interleukin-2/verapamil combination in advanced cancer. Eur J Cancer 1996;32A:1436-7.
35. Frost P, Ng CP, Belldegrun A, Bonavida B. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity. Cell Immunol 1997;180:70-83.
36. Bergmann-Leitner ES, Abrams SI. Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes. Cancer Immunol Immunother 2001;50:445-55.
37. O' Brien MC, Ueno T, Jahan N, Zajac-Kaye M, Mitsuya H. HIV-1 expression induced by anticancer agents in latently HIV-1-infected ACH2 cells. Biochem Biophys Res Commun 1995;207:903-9.
38. Hauck W, Stanner CP. Transcriptional regulation of the carcinoembryonic antigen gene. Identification of regulatory elements and multiple nuclear factors. J Biol Chem 1995;270:3602-10.
39. Schuetz JD, Collins JM, Wallace HJ, Diasio RB. Alteration of the secondary structure of newly synthesized DNA from murine bone marrow cells by 5-fluorouracil. Cancer Res 1986;46:119-23.
40. Glazer RJ, Lloyd LS. Association of cell lethality with incorporation of 5-fluorouracil and 5-fluorouridine into nuclear RNA in human colon carcinoma cells in culture. Mol Pharmacol 1982;21:468-73.
41. Dolnick BJ, Pink JJ. Effects of 5-fluorouracil on dihydrofolate reductase and dihydrofolate reductase mRNA from methotrexate-resistant KB cells. J Biol Chem 1985;260:3006-14.
42. Sierakowska H, Shulka RR, Dominski Z, Kole R. Inhibition of pre-mRNA splicing by 5-fluoro, 5-chloro-, and 5-bromouridine. J Biol Chem 1989;264:19185-91.
43. Patton JR, Jacobson MR, Pederson T. Pseudouridine formation in U2 small nuclear RNA. Proc Natl Acad Sci USA 1994;91:3324-8.
44. Lenz HJ, Manno DJ, Danenberg KD, Danenberg PV. Incorporation of 5-fluorouracil into U2 and U6 snRNA inhibits mRNA precursor splicing. J Biol Chem 1994;269:31962-8.
45. Allegra CJ, Grem JL. Antimetabolite. In: De Vita TV Jr, Hellman S, Rosenberg SA, eds. Cancer, principles & practice of oncology. 5th ed. New York, Philadelphia: Lippincott-Raven, 1997. 432-52.